Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2019 | Myeloma: real-world data

Evangelos Terpos • 15 Jun 2019
EHA 2019
Multiple Myeloma Dexamethasone Ixazomib Lenalidomide
INSIGHT-MM

Evangelos Terpos, MD, PhD, of University of Athens, Athens, Greece discusses how trial data corresponds to the real-world setting with regards to relapsed/refractory myeloma. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Evangelos Terpos

Long-term outcomes from the BelaRd trial and the evaluation of a VRA tool to guide belamaf dosing 2:38
Long-term outcomes from the BelaRd trial and the evaluation of a VRA tool to guide belamaf dosing
Evangelos Terpos • 12 May 2025
Advice for managing bone disease in multiple myeloma 3:25
Advice for managing bone disease in multiple myeloma
Evangelos Terpos • 12 May 2025
The potential of sustained MRD negativity to guide maintenance discontinuation post-SCT in myeloma 3:34
The potential of sustained MRD negativity to guide maintenance discontinuation post-SCT in myeloma
Evangelos Terpos • 12 May 2025
Isa-VCd followed by isa + len maintenance in newly diagnosed myeloma with severe renal impairment 0:57
Isa-VCd followed by isa + len maintenance in newly diagnosed myeloma with severe renal impairment
Evangelos Terpos • 6 Dec 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals